CSS »

Halozyme Therapeutics shares owned by CSS

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by CSS from 13F filings

Historical chart of CSS investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by CSS consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by CSS

Quarter filed Position value Share count Share price at filing
2023-12-31 $260k 300k 0.87
2023-03-31 $6.8M 8.0M 0.85

More positions owned by CSS

Royal Caribbean Group Note 6.000% 8/1 (Principal)
Noble Corp Ord Shs A (NE)
Ark Etf Tr Innovation Etf Call Option (ARKK)
American Airlines Group Note 6.500% 7/0 (Principal)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Mirati Therapeutics
Macom Tech Solutions Hldgs I Note 0.250% 3/1 (Principal)
Peabody Engr Corp Note 3.250% 3/0 (Principal)
Ionis Pharmaceuticals Note 4/0 (Principal)
Royal Caribbean Cruises Put Option (RCL)
Splunk Note 1.125% 9/1 (Principal)
American Airls Put Option (AAL)
Ncl Corp Note 5.375% 8/0 (Principal)
Marriott Vacations Worldwide Note 1/1 (Principal)
Brookdale Sr Living Unit 11/15/2025 (BKDT)

View all positions for CSS

Top funds holding Halozyme Therapeutics

Wellesley Investment Advisors
Davidson Kempner Capital Management
Lazard Asset Management
Citigroup
Aviva
Citadel Advisors
D. E. Shaw & Co
Wells Fargo & Company
Readystate Asset Management
Tenor Capital Management
Wolverine Asset Management
Victory Capital Management
Jpmorgan Chase & Co
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Shenkman Capital Management

View all funds holding Halozyme Therapeutics